Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
Titel:
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
Auteur:
Rugo, Hope S Lerebours, Florence Ciruelos, Eva Drullinsky, Pamela Ruiz-Borrego, Manuel Neven, Patrick Park, Yeon Hee Prat, Aleix Bachelot, Thomas Juric, Dejan Turner, Nicholas Sophos, Nickolas Zarate, Juan Pablo Arce, Christina Shen, Yu-Ming Turner, Stuart Kanakamedala, Hemanth Hsu, Wei-Chun Chia, Stephen